$21.23
+1.07 (+5.31%)
Open$20.01
Previous Close$20.16
Day High$21.38
Day Low$20.01
52W High$37.27
52W Low$6.88
Volume—
Avg Volume128.8K
Market Cap297.25M
P/E Ratio—
EPS$-1.99
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+18.4% upside
Current
$21.23
$21.23
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 808.7K | 64.19M | 65.56M |
| Net Income | -65,643,442 | 8.40M | 8.13M |
| Profit Margin | -8,123.7% | 13.1% | 12.4% |
| EBITDA | -70,237,992 | 15.55M | 13.35M |
| Free Cash Flow | — | 10.13M | 9.92M |
| Rev Growth | — | +4.7% | +24.1% |
| Debt/Equity | 0.00 | 0.89 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |